Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

被引：0
|
作者：
Juanjuan Zhao
Yongping Song
Delong Liu
机构：
[1] The first Affiliated Hospital of Zhengzhou University,Department of Oncology
[2] New York Medical College,Division of Hematology and Oncology
来源：
Biomarker Research | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoprostate cancer using magnetic resonance imagingxantrone, etoposide, cyclophosphamide’. Correction to: Biomark Res (2019) 7:19. https://doi.org/10.1186/s40364-019-0170-2
引用
收藏
相关论文
共 50 条
  • [31] FLT3 inhibitors in acute myeloid leukemia
    el-Shami, Khaled
    Stone, Richard M.
    Smith, B. Douglas
    EXPERT REVIEW OF HEMATOLOGY, 2008, 1 (02) : 153 - 160
  • [32] FLT3 inhibitors in acute myeloid leukemia
    Pastore, Domenico
    DRUGS AND CELL THERAPIES IN HEMATOLOGY, 2016, 4 (01): : 14 - 21
  • [33] Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel Lynn
    Morrissette, Jennifer J. D.
    Lieberman, David B.
    Watt, Christopher
    Schwartz, Gregory W.
    Faryabi, Robert B.
    Ferng, Timothy T.
    Shah, Neil P.
    Smith, Catherine C.
    Carroll, Martin
    Perl, Alexander E.
    BLOOD, 2017, 130
  • [34] Orally efficacious, selective FLT3 inhibitor for the treatment of acute myeloid leukemia
    Kreutter, Kevin
    Baindur, Nand
    Xu, Guozhang
    Kim, Alexander J.
    Baumann, Christian A.
    Tuman, Robert W.
    Johnson, Dana L.
    Gaul, Micheal D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [35] Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia
    Jarusiewicz, Jamie A.
    Jeon, Jae Yoon
    Connelly, Michele C.
    Chen, Yizhe
    Yang, Lei
    Baker, Sharyn D.
    Guy, R. Kiplin
    ACS OMEGA, 2017, 2 (05): : 1985 - 2009
  • [36] Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia
    Gregory, Mark A.
    Nemkov, Travis
    Reisz, Julie A.
    Zaberezhnyy, Vadym
    Hansen, Kirk C.
    D'Alessandro, Angelo
    DeGregori, James
    EXPERIMENTAL HEMATOLOGY, 2018, 58 : 52 - 58
  • [37] Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis
    Shai Shimony
    Jonathan Canaani
    Eitan Kugler
    Boaz Nachmias
    Ron Ram
    Israel Henig
    Avraham Frisch
    Chezi Ganzel
    Vladimir Vainstein
    Yakir Moshe
    Shlomzion Aumann
    Moshe Yeshurun
    Yishai Ofran
    Pia Raanani
    Ofir wolach
    Annals of Hematology, 2022, 101 : 2011 - 2011
  • [38] Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor
    Lou, Yin-jun
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (02) : 212 - 213
  • [39] A novel and potent FLT3 and IRAK4 dual inhibitor for the treatment of acute myeloid leukemia
    Yang, Rui
    Wu, Lei
    Zhang, Bing
    Xiang, Michael
    Wang, Suyue
    Xiang, Camille
    Lu, Zhijian
    Xiang, Jason
    CANCER RESEARCH, 2023, 83 (07)
  • [40] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
    Chen, Nianci
    Pan, Jiajia
    Zhou, Yile
    Mao, Liping
    Lou, Yinjun
    Qian, Jiejing
    Xu, Gaixiang
    Wei, Juying
    Zhou, De
    Shou, Lihong
    Li, Huang
    Yan, Minchao
    Zeng, Hui
    Fan, Cuihua
    Wu, Gongqiang
    Feng, Weiying
    Tong, Hongyan
    Jin, Jie
    Wang, Huafeng
    BLOOD, 2023, 142
12345